Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CNR2 | P34972 | 1/20 | 0.45 |
| ▸ | CDK5 | Q00535 | 6/20 | 0.44 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.44 |
| ▸ | ULK1 | O75385 | 2/20 | 0.40 |
| ▸ | ATR | Q13535 | 2/20 | 0.39 |
| ▸ | ITK | Q08881 | 3/20 | 0.39 |
| ▸ | ACSS2 | Q9NR19 | 2/20 | 0.39 |
| ▸ | PRF1 | P14222 | 1/20 | 0.39 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.38 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2927851 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1HPGDCNR2CDK5 | |
| SCHEMBL13515298 | 1.00 | KDM4E (0.50) | KDM4EALDH1A1HPGDCNR2CDK5 | |
| SCHEMBL2933637 | 0.79 | CDK5 (0.55) | KDM4EALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL2928266 | 0.73 | ALDH1A1 (0.55) | KDM4EALDH1A1ATRITK | |
| SCHEMBL2933583 | 0.72 | ITK (0.45) | KDM4EALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL27745020 | 0.72 | CDK5 (0.46) | KDM4ECDK5CDK5R1ATRITK | |
| SCHEMBL2928726 | 0.72 | ALDH1A1 (0.37) | ALDH1A1CDK5CDK5R1ATRITK | |
| SCHEMBL17422799 | 0.71 | CDK5 (0.57) | KDM4EALDH1A1HPGDCDK5CDK5R1 | |
| SCHEMBL2928728 | 0.71 | CYP2C9 (0.50) | KDM4EALDH1A1ITK | |
| SCHEMBL2930486 | 0.71 | CDK5 (0.44) | CDK5CDK5R1ATRITK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | claimed |
| CN-101472912-A | Pyridine and pyrazine derivatives as MNK kinase inhibitors | BIOVITRUM AB PUBL (SE) | 2009-07-01 | — | — | CN | claimed |
| EP-2044051-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (publ) (SE) | 2009-04-08 | — | — | EP | claimed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | claimed |
| WO-2007147874-A1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB (PUBL) (SE) | 2007-12-27 | — | — | WO | claimed |
| EP-2044051-B1 | PYRIDINE AND PYRAZINE DERIVATIVES AS MNK KINASE INHIBITORS | BIOVITRUM AB PUBL (SE) | 2010-01-27 | — | — | EP | disclosed |
| CN-101472912-A | Pyridine and pyrazine derivatives as MNK kinase inhibitors | BIOVITRUM AB PUBL (SE) | 2009-07-01 | — | — | CN | disclosed |
| US-20080039450-A1 | Compounds | BIOVITRUM AB (PUBL.) (SE) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080039450-A1 | Compounds | NEK2, CSNK2A3, CSNK2A1 | KDM4E 2380/4885ALDH1A1 3748/4885HPGD 3066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.